FINNENCE ▪ THE WIRE FILE
THE WIRE · № 76427
News■ Unclear/unknown
ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Clinical data supporting a diagnostic test could aid adoption, but the issuer is small and thinly traded.
Data supports niche diagnostic, limited market reach
CATALYST TO WATCH
Payer coverage or guideline inclusion
MAIN RISK
Small-cap liquidity and adoption risk
FULL DISPATCH
Studies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings alone FRIENDSWOOD, Texas, Oct. 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Corcept Seeks to Block Ex-Judge’s Testimony in Teva Antitrust Fight2026-10-12 20:58 UTC
Corcept Seeks to Block Ex-Judge’s Testimony in Teva Antitrust Fight2026-10-12 20:58 UTC
←CORRELATIONshares Healthcare
E2 Secures Dual FDA Clearances for the Hēlo® Platform, Introducing a PE Thrombectomy System with Integrated Blood Return2026-10-12 17:36 UTC
E2 Secures Dual FDA Clearances for the Hēlo® Platform, Introducing a PE Thrombectomy System with Integrated Blood Return2026-10-12 17:36 UTC
←CORRELATIONshares Healthcare
SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease2026-10-12 18:02 UTC
SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease2026-10-12 18:02 UTC
←CORRELATIONshares Healthcare
Is Picard Medical (NYSEAMERICAN:PMI) Overbought After a 12.87% Gain and an RSI of 74.6?2026-10-12 18:05 UTC
Is Picard Medical (NYSEAMERICAN:PMI) Overbought After a 12.87% Gain and an RSI of 74.6?2026-10-12 18:05 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.